ClinicalTrials.gg
CompletedNCT04377555Updated Feb 4, 2026

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

A Phase 4 interventional study of Ocrelizumab in Multiple Sclerosis, Relapsing, sponsored by Genentech, Inc.. Completed at 28 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2022, 3 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
179
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Enrollment
13th of 27
179 · median 170
Started
2020
with 4 others
Phase 4
11 of 27
1 open now
Registered
10th of 27
by date
Lead sponsor
2 of 27
Genentech, Inc.

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 13th largest by enrollment, is one of 5 that started in 2020, is one of 11 in phase 4, and was the 10th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The study plans to enroll approximately 150 participants (75 AA and 75 HA) with 50 participants enrolled in a CSF sub-study.

03

Conditions studied

  • Multiple Sclerosis, Relapsing
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RMS with Expanded Disability Status Scale (EDSS) 0-5.5 at enrollment
  • Participants who self-identify as Black or African American or Hispanic/Latino American
  • Treatment-naïve or initiating first or second switch from receiving treatment with certain disease modifying therapies (DMTs) including interferon or glatiramer acetate or dimethyl fumarate (DMF); or siponimod; or fingolimod; or diroximel fumarate; or teriflunomide; or ozanimod; or natalizumab
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable methods during the treatment period and for 6 months after the final dose of ocrelizumab
  • Neurologically stable for at least 30 days prior to randomization and baseline assessments

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of secondary progressive MS without relapses for at least 1 year (nonactive or inactive SPMS)
  • Primary Progressive Multiple Sclerosis (PPMS)
  • Participants with to gadolinium based contrast agent for MRI and participants who cannot tolerate MRI procedure
  • Infection Related
  • Cancer Related
  • Pregnant or lactating, or intending to become pregnant during the study
  • Other Medical Conditions
  • Known presence or history of other neurologic disorders
  • Vaccinations: Receipt of a , or attenuated, or inactivated / component vaccine within 6 weeks prior to first administration of ocrelizumab
  • Laboratory: abnormalities or findings at screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
179 participants (actual)

Study arms

  • Experimental
    All Participants

    Main study participants will be evaluated at baseline, monitored and followed for a 1 year period with the option to participate in a 1 year extension. Participants in the CSF substudy will be followed for two years and will receive two additional doses of 600 mg ocrelizumab at Weeks 48 and 72.

    Drug: Ocrelizumab

Interventions

  • Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Free of Any Protocol-defined Events During a 48-week Period on Treatment

    A protocol-defined event is the occurrence of at least one of the following: a protocol-defined relapse; a 24-week Confirmed Disability Progression event; a T1 Gd-enhancing lesion or new and/or enlarging T2 lesion on brain magnetic resonance imaging (MRI)

    Time frame: 48 Weeks

Secondary outcomes

  1. Time to onset of 24 weeks confirmed disability progression (CDP) at week 48

    Time frame: Week 48

  2. Time to protocol-defined event

    A protocol-defined event is the occurrence of at least one of the following: a protocol-defined relapse; a 24-week Confirmed Disability Progression event; a T1 Gd-enhancing lesion or new and/or enlarging T2 lesion on brain MRI

    Time frame: Week 48

  3. Annualized relapse rate at week 48

    Time frame: Week 48

07

Study locations

28 sites
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • Keck School of Medicine of USC
    Los Angeles, California 90033-5315, United States
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • Baptist Neurology - Beaches
    Jacksonville Beach, Florida 32250, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Shepherd Center Inc.
    Atlanta, Georgia 30309, United States
  • Atlanta Neuroscience Institute
    Atlanta, Georgia 30327, United States
  • Rush University Medical Center
    Chicago, Illinois 60612-3244, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Josephson Wallack Munshower Neurology PC
    Indianapolis, Indiana 46256, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201-1642, United States
  • Johns Hopkins University Neurology Research Office
    Baltimore, Maryland 21287, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Paramus, New Jersey 07652, United States
  • SUNY Upstate Medical Center
    Syracuse, New York 13210, United States
  • Guilford Neurologic Research Partners, LLC
    Greensboro, North Carolina 27401, United States
  • Jefferson University Hospitals, Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Neurology Clinic - Cordova
    Cordova, Tennessee 38018, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37204, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic
    Frisco, Texas 75034, United States
  • Baylor College of Medicine Medical Center
    Houston, Texas 77030, United States
  • Multiple Sclerosis Center of Tidewater
    Norfolk, Virginia 23502, United States
  • Wheaton Franciscan Healthcare - St. Francis Outpatient Center
    Milwaukee, Wisconsin 53215, United States
  • Froedtert and The Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • The Aga Khan University-Kenya.
    Nairobi, 00100, Kenya
  • Centro Internacional De Mercadeo
    Guaynabo, 969, Puerto Rico
08

References and documents

Publications

  • Williams MJ, Okai AF, Cross AH, Monson NL, Vartanian T, Thrower BW, Reder AT, English JB, Wu GF, Bernitsas E, Yap S, Ndrio J, Pei J, Mowry EM, Magrini F, Acosta J, Amezcua L; CHIMES investigators. Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Mult Scler Relat Disord. 2023 Aug;76:104794. doi: 10.1016/j.msard.2023.104794. Epub 2023 Jun 9. PubMed 37356256 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Dec 2022, 28 months.

Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 28 months is close to that.

Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2020
First posted
May 6, 2020
StartActual
Jul 30, 2020
Primary completionActual
Dec 15, 2022
CompletionActual
Nov 11, 2025
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04377555
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 6, 2020
Start date
Jul 30, 2020
Primary completion
Dec 15, 2022
Completion
Nov 11, 2025
Last update
Feb 4, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion